Trovagene Reports Flat Q3 Revenues; Halves Net Loss | GenomeWeb

This article has been updated from a previous version to include comments from Trovagene's Q3 earnings call.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Monday flat year-over-year third quarter revenues as it trimmed its net loss in half.

For the three months ended Sept. 30, 2015, the San Diego-based molecular diagnostics developer reported $57,000 in revenues. The company reported $51,000 in royalty revenue compared to $57,000 a year ago, and $6,000 in diagnostic service revenue compared to none in Q3 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.